

Researcher Information Form

Name: Elyse E Lower

Department/Division/College: Heme and Onc/COM

Room/Address:

Holmes Suite 1001
University of Cincinnati Academic Health Center
200 Albert B. Sabin Way
Cincinnati, OH 45267-0565

Phone: 513-584-3810

Email: lowere@ucmail.uc.edu

Research Interest (1-2 Sentences):

Prognostic factors in breast cancer, alternative therapies for interstitial lung diseases.

Unique Resources/Techniques:

Breast Cancer Treatment and Tissue Samples

Representative Publications (5 Maximum, May use Hyperlink):

Kittaneh, Muaiad; Badve, Sunil; Caldera, Humberto; Coleman, Robert; Goetz, Matthew P; Mahtani, Reshma; Mamounas, Eleftherios; Kalinsky, Kevin; **Lower, Elyse**; Pegram, Mark; Press, Michael F; Rugo, Hope S; Schwartzberg, Lee; Traina, Tiffany; Vogel, Charles (2020) Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical breast cancer.

Walaszek K, **Lower EE**, Ziolkowski P, Weber GF. Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis. Br J Cancer. (2018) Nov; 119(10):1259-1266.

Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, **Lower EE**, Mahtani R, Terry Mamounas E, Pegram M, Vogel C; Breast Cancer Therapy Expert Group (BCTEG). Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Res Treat. (2018) Aug;171(1):11-20

Yang Y, Leonard M, Zhang Y, Zhao, D, Mahmoud C, Khan S, Wang J, **Lower EE**, and Zhang X. HER2-driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator (2018) Cancer Research 78(2):422-435.

Ruiz-Torres SJ, Benight NM, Karns RA, **Lower EE**, Guan JL, Waltz SE. HGFL-mediated RON signaling supports breast cancer stem cell phenotypes via activation of non-canonical β -catenin signaling. *Oncotarget*. (2017) Jul 22;8(35):58918-58933.